These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. In vivo characterization of the mitochondrial selective K(ATP) opener (3R)-trans-4-((4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)dimethyl-2H-1-benzopyran-6-carbonitril monohydrochloride (BMS-191095): cardioprotective, hemodynamic, and electrophysiological effects. Grover GJ; D'Alonzo AJ; Darbenzio RB; Parham CS; Hess TA; Bathala MS J Pharmacol Exp Ther; 2002 Oct; 303(1):132-40. PubMed ID: 12235243 [TBL] [Abstract][Full Text] [Related]
5. Cardioselective antiischemic ATP-sensitive potassium channel (K(ATP)) openers. 6. Effect of modifications at C6 of benzopyranyl cyanoguanidines. Ding CZ; Rovnyak GC; Misra RN; Grover GJ; Miller AV; Ahmed SZ; Kelly Y; Normandin DE; Sleph PG; Atwal KS J Med Chem; 1999 Sep; 42(18):3711-7. PubMed ID: 10479302 [TBL] [Abstract][Full Text] [Related]
6. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies. Docherty JC; Gunter HE; Kuzio B; Shoemaker L; Yang L; Deslauriers R J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352 [TBL] [Abstract][Full Text] [Related]
7. Cardioprotective effects of a novel calcium antagonist related to the structure of cromakalim. Grover GJ; Sleph PG; Dzwonczyk S; McCullough JR J Pharmacol Exp Ther; 1993 Oct; 267(1):102-7. PubMed ID: 8229736 [TBL] [Abstract][Full Text] [Related]
8. KR-31762, a novel KATP channel opener, exerts cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury. Lee SH; Yang MK; Lim JH; Seo HW; Yi KY; Yoo SE; Lee BH; Won HS; Lee CS; Choi WS; Shin HS Arch Pharm Res; 2008 Apr; 31(4):482-9. PubMed ID: 18449506 [TBL] [Abstract][Full Text] [Related]
9. BMS-180448, a novel glyburide-reversible cardioprotective agent, enhances postischemic recovery of contractile function in dogs. Grover GJ; Parham CS; Whigan DB; Mitroka JG J Pharmacol Exp Ther; 1996 Feb; 276(2):380-7. PubMed ID: 8632300 [TBL] [Abstract][Full Text] [Related]
10. Effect of timing of treatment of the glyburide-reversible cardioprotective activity of BMS-180448. Gomoll AW; Roth RA; Swillo RE; Baird AJ; Sargent CS; Behling RW; Malone HJ; Grover GJ J Pharmacol Exp Ther; 1997 Apr; 281(1):24-33. PubMed ID: 9103476 [TBL] [Abstract][Full Text] [Related]
11. The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism. Grover GJ; D'Alonzo AJ; Sleph PG; Dzwonczyk S; Hess TA; Darbenzio RB J Pharmacol Exp Ther; 1994 May; 269(2):536-40. PubMed ID: 8182522 [TBL] [Abstract][Full Text] [Related]
13. Effects of ATP-sensitive potassium channel activators diazoxide and BMS-191095 on membrane potential and reactive oxygen species production in isolated piglet mitochondria. Busija DW; Katakam P; Rajapakse NC; Kis B; Grover G; Domoki F; Bari F Brain Res Bull; 2005 Jul; 66(2):85-90. PubMed ID: 15982523 [TBL] [Abstract][Full Text] [Related]
14. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents. Sargent CA; Smith MA; Dzwonczyk S; Sleph PG; Grover GJ J Pharmacol Exp Ther; 1991 Oct; 259(1):97-103. PubMed ID: 1920138 [TBL] [Abstract][Full Text] [Related]
15. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts? Tosaki A; Szerdahelyi P; Engelman RM; Das DK J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798 [TBL] [Abstract][Full Text] [Related]
20. Activation of ATP-sensitive K+ channels by cromakalim. Effects on cellular K+ loss and cardiac function in ischemic and reperfused mammalian ventricle. Venkatesh N; Stuart JS; Lamp ST; Alexander LD; Weiss JN Circ Res; 1992 Dec; 71(6):1324-33. PubMed ID: 1423930 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]